Adverse Effects of Trospium
Introduction to Adverse Effects
- The American College of Physicians guideline reports that trospium causes anticholinergic side effects, including dry mouth and constipation, with a moderate risk of treatment discontinuation due to adverse effects 1, 2, 3
Most Common Side Effects
- Dry mouth is the most frequently reported anticholinergic effect of trospium 2
- Constipation is the second most common side effect of trospium 2
- Blurred vision is a typical antimuscarinic effect of trospium 2, 4
- Dizziness is notably more frequent with trospium compared to oxybutynin 2, 3, 4
Quantified Risk Profile
- The American College of Physicians guideline provides a number needed to harm (NNTH) of 8 [CI, 6 to 11] for trospium, meaning for every 8 patients treated, one will experience an adverse effect compared to placebo (moderate-quality evidence) 2, 3, 4
- The discontinuation NNTH for trospium is 56 [CI, 30 to 228], indicating that for every 56 patients treated, one will discontinue due to adverse effects compared to placebo (high-quality evidence) 2, 3, 4
Comparative Tolerability Context
- Trospium is better tolerated than oxybutynin and fesoterodine, but less well tolerated than tolterodine and darifenacin 2, 4
- Dizziness is a distinguishing feature of trospium, reported more frequently than with oxybutynin 2, 3, 4